Skip to main content
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1985 Aug;76(2):875–877. doi: 10.1172/JCI112045

Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor.

J S McDougal, L S Martin, S P Cort, M Mozen, C M Heldebrant, B L Evatt
PMCID: PMC423922  PMID: 2993366

Abstract

The virus that causes the acquired immunodeficiency syndrome (AIDS), human T lymphotropic virus/lymphadenopathy-associated virus (HTLV-III/LAV), was incubated at temperatures from 37 degrees to 60 degrees C and virus titer (ID-50) was determined over time by a microculture infectivity assay. The rate of thermal decay was consistent with first-order kinetics, and these data were used to construct a linear Arrhenius plot (r = 0.99), which was used to determine inactivation time as a function of temperature. In the liquid state, thermal decay was little affected by matrix (culture media, serum, or liquid Factor VIII). In the lyophilized state, the time required to reduce virus titer 10-fold (1 log) at 60 degrees C was 32 min compared with 24 s in the liquid state. HTLV-III/LAV in liquid antihemophilic Factor VIII or IX was lyophilized and heated according to commercial manufacturers' specifications. Infectious virus was undetectable with these regimens. Heat treatment should reduce or stop transmission of HTLV-III/LAV by commercial antihemophilic Factor VIII or IX.

Full text

PDF
875

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Levy J. A., Mitra G., Mozen M. M. Recovery and inactivation of infectious retroviruses from factor VIII concentration. Lancet. 1984 Sep 29;2(8405):722–723. doi: 10.1016/s0140-6736(84)92627-8. [DOI] [PubMed] [Google Scholar]
  2. McDougal J. S., Cort S. P., Kennedy M. S., Cabridilla C. D., Feorino P. M., Francis D. P., Hicks D., Kalyanaraman V. S., Martin L. S. Immunoassay for the detection and quantitation of infectious human retrovirus, lymphadenopathy-associated virus (LAV). J Immunol Methods. 1985 Jan 21;76(1):171–183. doi: 10.1016/0022-1759(85)90489-2. [DOI] [PubMed] [Google Scholar]
  3. Rouzioux C., Chamaret S., Montagnier L., Carnelli V., Rolland G., Mannucci P. M. Absence of antibodies to AIDS virus in haemophiliacs treated with heat-treated Factor VIII concentrate. Lancet. 1985 Feb 2;1(8423):271–272. doi: 10.1016/s0140-6736(85)91043-8. [DOI] [PubMed] [Google Scholar]
  4. Spire B., Dormont D., Barré-Sinoussi F., Montagnier L., Chermann J. C. Inactivation of lymphadenopathy-associated virus by heat, gamma rays, and ultraviolet light. Lancet. 1985 Jan 26;1(8422):188–189. doi: 10.1016/s0140-6736(85)92026-4. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES